$6.5 Million Advances Nasal Vaccines Targeting Parasites, Viruses, and Bacteria

Vaxinano, a biotech company specializing in developing prophylactic and therapeutic nasal vaccines, has successfully raised €6 million in a funding round.

Thanks to its Stellar-NP nanoparticle technology, Vaxinano is developing a new generation of highly stable, adjuvant-free nasal vaccines designed to deliver effective and long-lasting responses to the most challenging pathogens, including parasites, viruses, and bacteria.

The platform has demonstrated preventive and therapeutic efficacy across multiple species and various infectious diseases, such as leishmaniasis, toxoplasmosis, and colibacillosis.

Didier Betbeder, founder and CSO of Vaxinano, stated in a press release on October 29, 2024, "The Stellar-NP technology has the potential to revolutionize the vaccine landscape by providing more effective and cost-efficient solutions in a context of emerging pandemics."